S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
S&P 500   4,320.06 (-0.23%)
DOW   33,963.84 (-0.31%)
QQQ   357.91 (+0.01%)
AAPL   174.79 (+0.49%)
MSFT   317.01 (-0.79%)
META   299.08 (+1.13%)
GOOGL   130.25 (-0.15%)
AMZN   129.12 (-0.16%)
TSLA   244.88 (-4.23%)
NVDA   416.10 (+1.45%)
NIO   8.53 (+0.95%)
BABA   88.30 (+4.98%)
AMD   96.20 (+0.09%)
T   15.12 (-1.24%)
F   12.43 (+1.89%)
MU   68.88 (+1.44%)
CGC   0.84 (+9.48%)
GE   111.25 (-1.54%)
DIS   81.25 (-1.79%)
AMC   7.62 (-1.04%)
PFE   32.69 (-0.49%)
PYPL   57.88 (-1.26%)
NFLX   379.81 (-1.13%)
NASDAQ:UTHR

United Therapeutics (UTHR) Stock Forecast, Price & News

$222.75
-0.93 (-0.42%)
(As of 05:25 PM ET)
Compare
Today's Range
$221.82
$225.00
50-Day Range
$217.48
$248.24
52-Week Range
$202.31
$283.09
Volume
163,673 shs
Average Volume
424,930 shs
Market Capitalization
$10.45 billion
P/E Ratio
12.60
Dividend Yield
N/A
Price Target
$296.44

United Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
32.0% Upside
$296.44 Price Target
Short Interest
Healthy
2.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.00
Upright™ Environmental Score
News Sentiment
1.06mentions of United Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$4.74 M Sold Last Quarter
Proj. Earnings Growth
9.34%
From $18.95 to $20.72 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.20 out of 5 stars

Medical Sector

16th out of 968 stocks

Pharmaceutical Preparations Industry

5th out of 445 stocks


UTHR stock logo

About United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

UTHR Price History

UTHR Stock News Headlines

Advisor to FBI: Sell META now
Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.
Advisor to FBI: Sell META now
Stocks just keep going up. But all isn’t what it seems, according to an FBI and Pentagon advisor. Find out what he knows, here.
Goldman Sachs Remains a Sell on United Therapeutics (UTHR)
See More Headlines
Receive UTHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

UTHR Company Calendar

Last Earnings
8/02/2023
Today
9/22/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:UTHR
CUSIP
91307C10
Employees
985
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$296.44
High Stock Price Forecast
$375.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
+32.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$727.30 million
Pretax Margin
52.98%

Debt

Sales & Book Value

Annual Sales
$1.94 billion
Cash Flow
$17.07 per share
Book Value
$105.24 per share

Miscellaneous

Free Float
41,066,000
Market Cap
$10.50 billion
Optionable
Optionable
Beta
0.62

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Martine A. Rothblatt J.D.Dr. Martine A. Rothblatt J.D. (Age 68)
    M.B.A., Ph.D., Founder, Chairman & CEO
    Comp: $5.32M
  • Mr. Michael I. Benkowitz (Age 51)
    Pres & COO
    Comp: $2.83M
  • Mr. James C. Edgemond (Age 55)
    CFO & Treasurer
    Comp: $2.01M
  • Mr. Paul A. Mahon J.D.Mr. Paul A. Mahon J.D. (Age 59)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $2.31M
  • Mr. Dewey Steadman C.F.A.
    Head of Investor Relations
  • Ms. Holly Hobson
    Associate VP of HR
  • Kevin T. Gray
    Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson (Age 55)
    Exec. VP of Technical Operations
  • Dr. Leigh Peterson
    Sr. VP of Product Devel.
  • Mr. Gil Golden
    Sr. VP & Chief Medical Officer













UTHR Stock - Frequently Asked Questions

Should I buy or sell United Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings
or view top-rated stocks.

What is United Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 1-year price objectives for United Therapeutics' stock. Their UTHR share price forecasts range from $230.00 to $375.00. On average, they predict the company's share price to reach $296.44 in the next twelve months. This suggests a possible upside of 33.1% from the stock's current price.
View analysts price targets for UTHR
or view top-rated stocks among Wall Street analysts.

How have UTHR shares performed in 2023?

United Therapeutics' stock was trading at $278.09 on January 1st, 2023. Since then, UTHR shares have decreased by 19.9% and is now trading at $222.75.
View the best growth stocks for 2023 here
.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,090,000 shares, a drop of 42.3% from the August 15th total of 1,890,000 shares. Based on an average daily trading volume, of 332,900 shares, the days-to-cover ratio is presently 3.3 days.
View United Therapeutics' Short Interest
.

When is United Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our UTHR earnings forecast
.

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, August, 2nd. The biotechnology company reported $5.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.57 by $0.67. The biotechnology company had revenue of $596.50 million for the quarter, compared to the consensus estimate of $524.18 million. United Therapeutics had a trailing twelve-month return on equity of 17.52% and a net margin of 41.29%. United Therapeutics's quarterly revenue was up 27.8% compared to the same quarter last year. During the same period last year, the company earned $2.41 EPS.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.86%), Renaissance Technologies LLC (4.66%), State Street Corp (4.00%), Geode Capital Management LLC (1.72%), Bank of New York Mellon Corp (1.27%) and Dimensional Fund Advisors LP (1.14%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends
.

How do I buy shares of United Therapeutics?

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $222.75.

How much money does United Therapeutics make?

United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.45 billion and generates $1.94 billion in revenue each year. The biotechnology company earns $727.30 million in net income (profit) each year or $17.68 on an earnings per share basis.

How many employees does United Therapeutics have?

The company employs 985 workers across the globe.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for the company is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at ir@unither.com, or via fax at 301-608-9291.

This page (NASDAQ:UTHR) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -